News ViiV's Waterhouse exits to take the CEO job at CSL CSL has named Deborah Waterhouse as its new chief executive, on the same day her departure from the same role at ViiV was announced.
News CSL joins forces with Alentis on claudin candidate CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.
News UK first country to launch CSL's trivalent flu shot Aujemflu CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.
News White House signs pricing deals with nine more pharmas Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
News Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
News Falling flu vaccine sales in US stall CSL's Seqirus spinout CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.